Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GNAI3 | P08754 | 5/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 5/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 5/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25075131 | 1.00 | NPC1 (0.39) | NPC1GNAI3GNAO1GNAI1HSD11B1 | |
| SCHEMBL26494156 | 1.00 | NPC1 (0.39) | NPC1GNAI3GNAO1GNAI1HSD11B1 | |
| SCHEMBL26494158 | 0.92 | NPC1 (0.43) | NPC1GNAI3GNAO1GNAI1HSD11B1 | |
| SCHEMBL25075138 | 0.92 | NPC1 (0.43) | NPC1GNAI3GNAO1GNAI1HSD11B1 | |
| SCHEMBL26494363 | 0.92 | NPC1 (0.43) | NPC1GNAI3GNAO1GNAI1HSD11B1 | |
| SCHEMBL25075447 | 0.92 | NPC1 (0.41) | NPC1GNAI3GNAO1GNAI1HSD11B1 | |
| SCHEMBL26494190 | 0.92 | NPC1 (0.41) | NPC1GNAI3GNAO1GNAI1HSD11B1 | |
| SCHEMBL25075134 | 0.91 | NPC1 (0.40) | NPC1GNAI3GNAO1GNAI1HSD11B1 | |
| SCHEMBL25075121 | 0.86 | BIRC2 (0.38) | NPC1GNAI3GNAO1GNAI1ALDH1A1 | |
| SCHEMBL25075104 | 0.86 | BIRC2 (0.38) | NPC1GNAI3GNAO1GNAI1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2023023537-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. (US) | 2023-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | BTK, BCL9, CRBN | NPC1 4398/4885GNAI3 1728/4885GNAO1 3018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.